MaxCyte, Inc. Appoints Cenk Sumen Chief Scientific Officer

GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cellular engineering company focused on providing enabling platform technologies for to advance research-based research and the discovery, development and commercialization of next-generation cell therapies, Cenk Sumen, Ph.D., announced today as Chief Scientific Officer (CSO). With a proven track record in scientific, technology, and business development expertise, Dr. Sumen brings experience in technology, application, and platform assessments, developing business partnerships, and leading cross-departmental collaboration to accelerate scientific and technical management.

“We are delighted to have Cenk join the MaxCyte team as his career has demonstrated a wealth of experience in science, technology, business development and corporate strategy,” said Doug Doerfler, CEO, President and Founder of MaxCyte. “He is a welcome and important addition to our leadership team and will be invaluable in helping to support our cell therapy partners with MaxCyte’s technology. The management team and I look forward to working with Dr. Sumen to continuously identify growth opportunities enabling the cell therapy industry and implement our strategic vision to expand our scientific and product offerings.

“I am driven by scientific innovation and work with visionary companies that truly have a beneficial impact on the health of humanity,” said Cenk Sumen, CSO at MaxCyte. “I look forward to ensuring that MaxCyte’s platforms are positioned as the solution of choice for our customers’ cellular engineering needs while synergistically leading the scientific and technical direction with the collective teams within the company. organization to help expand MaxCyte’s position in the cell engineering and cell therapy and bioprocessing markets.

Dr. Sumen comes to MaxCyte from Stemson Therapeutics, where he was Chief Technology Officer and led all aspects of technology, scaling, process development and automation. Previously, he spent over a decade focusing on scientific innovation and business development strategy for companies such as Thermo Fisher Scientific and Hitachi Chemical Advanced Therapeutics Solutions. Dr. Sumen holds a Ph.D. in Microbiology and Immunology from Stanford University, postdoctoral training at Harvard, and fellowship at the Cancer Research Institute, working at Memorial Sloan Kettering Cancer Center under the direction of Nobel Laureate Dr. Jim Allison. Additionally, Dr. Sumen is an Adjunct Professor in the Department of Chemical and Biomolecular Engineering at NYU Tandon School of Engineering. He is passionate about the opportunity to teach and guide students both in the classroom and towards successful careers in industry and academia.

About Maxcyte
MaxCyte is a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell research and the discovery, development and commercialization of next-generation cell therapies. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates the complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our flow electroporation technology, was designed to support the growing cell therapy market and can be used across the continuum of the high-growth cell therapy industry. , from discovery and development to commercialization of the next generation, cell-based medicines. The ExPERT product family includes: four instruments, ATx™, STx™, GTx™ and VLx™; a portfolio of treatment assemblies or proprietary disposables; and software protocols, all backed by a strong global intellectual property portfolio.